Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization

Benjamin A. Mooso, Ruth Louise Vinall, Clifford G Tepper, Rosalinda M. Savoy, Jean P. Cheung, Sheetal Singh, Salma Siddiqui, Yu Wang, Roble G. Bedolla, Anthony Martinez, Maria Mudryj, Hsing-Jien Kung, Ralph W deVere White, Paramita M Ghosh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

As prostate cancer (CaP) is regulated by androgen receptor (AR) activity, metastatic CaP is treated with androgen deprivation therapy (ADT). Despite initial response, patients on ADT eventually progress to castration-resistant CaP (CRPC), which is currently incurable. We previously showed that cleavage of the 280 kDa structural protein Filamin A (FlnA) to a 90 kDa fragment, and nuclear localization of the cleaved product, sensitized CRPC cells to ADT. Hence, treatment promoting FlnA nuclear localization would enhance androgen responsiveness. Here, we show that FlnA nuclear localization induced apoptosis in CRPC cells during ADT, identifying it as a treatment tool in advanced CaP. Significantly, the natural product genistein combined polysaccharide (GCP) had a similar effect. Investigation of the mechanism of GCP-induced apoptosis showed that GCP induced FlnA cleavage and nuclear localization and that apoptosis resulting from GCP treatment was mediated by FlnA nuclear localization. Two main components of GCP are genistein and daidzein: the ability of GCP to induce G2 arrest was due to genistein whereas sensitivity to ADT stemmed from daidzein; hence, both were needed to mediate GCP's effects. FlnA cleavage is regulated by its phosphorylation; we show that ADT enhanced FlnA phosphorylation, which prevented its cleavage, whereas GCP inhibited FlnA phosphorylation, thereby sensitizing CaP cells to ADT. In a mouse model of CaP recurrence, GCP, but not vehicle, impeded relapse following castration, indicating that GCP, when administered with ADT, interrupted the development of CRPC. These results demonstrate the efficacy of GCP in promoting FlnA nuclear localization and enhancing androgen responsiveness in CaP.

Original languageEnglish (US)
Pages (from-to)759-777
Number of pages19
JournalEndocrine-Related Cancer
Volume19
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Filamins
Androgens
Prostatic Neoplasms
Therapeutics
Genistein
Castration
Phosphorylation
Apoptosis
genistein combined polysaccharide
Recurrence
Androgen Receptors
Biological Products

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. / Mooso, Benjamin A.; Vinall, Ruth Louise; Tepper, Clifford G; Savoy, Rosalinda M.; Cheung, Jean P.; Singh, Sheetal; Siddiqui, Salma; Wang, Yu; Bedolla, Roble G.; Martinez, Anthony; Mudryj, Maria; Kung, Hsing-Jien; deVere White, Ralph W; Ghosh, Paramita M.

In: Endocrine-Related Cancer, Vol. 19, No. 6, 12.2012, p. 759-777.

Research output: Contribution to journalArticle

Mooso, Benjamin A. ; Vinall, Ruth Louise ; Tepper, Clifford G ; Savoy, Rosalinda M. ; Cheung, Jean P. ; Singh, Sheetal ; Siddiqui, Salma ; Wang, Yu ; Bedolla, Roble G. ; Martinez, Anthony ; Mudryj, Maria ; Kung, Hsing-Jien ; deVere White, Ralph W ; Ghosh, Paramita M. / Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. In: Endocrine-Related Cancer. 2012 ; Vol. 19, No. 6. pp. 759-777.
@article{be7ce045d8ce4febaf37ae232061efbe,
title = "Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization",
abstract = "As prostate cancer (CaP) is regulated by androgen receptor (AR) activity, metastatic CaP is treated with androgen deprivation therapy (ADT). Despite initial response, patients on ADT eventually progress to castration-resistant CaP (CRPC), which is currently incurable. We previously showed that cleavage of the 280 kDa structural protein Filamin A (FlnA) to a 90 kDa fragment, and nuclear localization of the cleaved product, sensitized CRPC cells to ADT. Hence, treatment promoting FlnA nuclear localization would enhance androgen responsiveness. Here, we show that FlnA nuclear localization induced apoptosis in CRPC cells during ADT, identifying it as a treatment tool in advanced CaP. Significantly, the natural product genistein combined polysaccharide (GCP) had a similar effect. Investigation of the mechanism of GCP-induced apoptosis showed that GCP induced FlnA cleavage and nuclear localization and that apoptosis resulting from GCP treatment was mediated by FlnA nuclear localization. Two main components of GCP are genistein and daidzein: the ability of GCP to induce G2 arrest was due to genistein whereas sensitivity to ADT stemmed from daidzein; hence, both were needed to mediate GCP's effects. FlnA cleavage is regulated by its phosphorylation; we show that ADT enhanced FlnA phosphorylation, which prevented its cleavage, whereas GCP inhibited FlnA phosphorylation, thereby sensitizing CaP cells to ADT. In a mouse model of CaP recurrence, GCP, but not vehicle, impeded relapse following castration, indicating that GCP, when administered with ADT, interrupted the development of CRPC. These results demonstrate the efficacy of GCP in promoting FlnA nuclear localization and enhancing androgen responsiveness in CaP.",
author = "Mooso, {Benjamin A.} and Vinall, {Ruth Louise} and Tepper, {Clifford G} and Savoy, {Rosalinda M.} and Cheung, {Jean P.} and Sheetal Singh and Salma Siddiqui and Yu Wang and Bedolla, {Roble G.} and Anthony Martinez and Maria Mudryj and Hsing-Jien Kung and {deVere White}, {Ralph W} and Ghosh, {Paramita M}",
year = "2012",
month = "12",
doi = "10.1530/ERC-12-0171",
language = "English (US)",
volume = "19",
pages = "759--777",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "6",

}

TY - JOUR

T1 - Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization

AU - Mooso, Benjamin A.

AU - Vinall, Ruth Louise

AU - Tepper, Clifford G

AU - Savoy, Rosalinda M.

AU - Cheung, Jean P.

AU - Singh, Sheetal

AU - Siddiqui, Salma

AU - Wang, Yu

AU - Bedolla, Roble G.

AU - Martinez, Anthony

AU - Mudryj, Maria

AU - Kung, Hsing-Jien

AU - deVere White, Ralph W

AU - Ghosh, Paramita M

PY - 2012/12

Y1 - 2012/12

N2 - As prostate cancer (CaP) is regulated by androgen receptor (AR) activity, metastatic CaP is treated with androgen deprivation therapy (ADT). Despite initial response, patients on ADT eventually progress to castration-resistant CaP (CRPC), which is currently incurable. We previously showed that cleavage of the 280 kDa structural protein Filamin A (FlnA) to a 90 kDa fragment, and nuclear localization of the cleaved product, sensitized CRPC cells to ADT. Hence, treatment promoting FlnA nuclear localization would enhance androgen responsiveness. Here, we show that FlnA nuclear localization induced apoptosis in CRPC cells during ADT, identifying it as a treatment tool in advanced CaP. Significantly, the natural product genistein combined polysaccharide (GCP) had a similar effect. Investigation of the mechanism of GCP-induced apoptosis showed that GCP induced FlnA cleavage and nuclear localization and that apoptosis resulting from GCP treatment was mediated by FlnA nuclear localization. Two main components of GCP are genistein and daidzein: the ability of GCP to induce G2 arrest was due to genistein whereas sensitivity to ADT stemmed from daidzein; hence, both were needed to mediate GCP's effects. FlnA cleavage is regulated by its phosphorylation; we show that ADT enhanced FlnA phosphorylation, which prevented its cleavage, whereas GCP inhibited FlnA phosphorylation, thereby sensitizing CaP cells to ADT. In a mouse model of CaP recurrence, GCP, but not vehicle, impeded relapse following castration, indicating that GCP, when administered with ADT, interrupted the development of CRPC. These results demonstrate the efficacy of GCP in promoting FlnA nuclear localization and enhancing androgen responsiveness in CaP.

AB - As prostate cancer (CaP) is regulated by androgen receptor (AR) activity, metastatic CaP is treated with androgen deprivation therapy (ADT). Despite initial response, patients on ADT eventually progress to castration-resistant CaP (CRPC), which is currently incurable. We previously showed that cleavage of the 280 kDa structural protein Filamin A (FlnA) to a 90 kDa fragment, and nuclear localization of the cleaved product, sensitized CRPC cells to ADT. Hence, treatment promoting FlnA nuclear localization would enhance androgen responsiveness. Here, we show that FlnA nuclear localization induced apoptosis in CRPC cells during ADT, identifying it as a treatment tool in advanced CaP. Significantly, the natural product genistein combined polysaccharide (GCP) had a similar effect. Investigation of the mechanism of GCP-induced apoptosis showed that GCP induced FlnA cleavage and nuclear localization and that apoptosis resulting from GCP treatment was mediated by FlnA nuclear localization. Two main components of GCP are genistein and daidzein: the ability of GCP to induce G2 arrest was due to genistein whereas sensitivity to ADT stemmed from daidzein; hence, both were needed to mediate GCP's effects. FlnA cleavage is regulated by its phosphorylation; we show that ADT enhanced FlnA phosphorylation, which prevented its cleavage, whereas GCP inhibited FlnA phosphorylation, thereby sensitizing CaP cells to ADT. In a mouse model of CaP recurrence, GCP, but not vehicle, impeded relapse following castration, indicating that GCP, when administered with ADT, interrupted the development of CRPC. These results demonstrate the efficacy of GCP in promoting FlnA nuclear localization and enhancing androgen responsiveness in CaP.

UR - http://www.scopus.com/inward/record.url?scp=84869219105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869219105&partnerID=8YFLogxK

U2 - 10.1530/ERC-12-0171

DO - 10.1530/ERC-12-0171

M3 - Article

VL - 19

SP - 759

EP - 777

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 6

ER -